171 related articles for article (PubMed ID: 38218749)
21. Apatinib enhanced anti-tumor activity of cisplatin on triple-negative breast cancer through inhibition of VEGFR-2.
Gao Z; Shi M; Wang Y; Chen J; Ou Y
Pathol Res Pract; 2019 Jul; 215(7):152422. PubMed ID: 31079851
[TBL] [Abstract][Full Text] [Related]
22. Circular RNA UBAP2 facilitates the cisplatin resistance of triple-negative breast cancer via microRNA-300/anti-silencing function 1B histone chaperone/PI3K/AKT/mTOR axis.
Wang L; Yang X; Zhou F; Sun X; Li S
Bioengineered; 2022 Mar; 13(3):7197-7208. PubMed ID: 35263216
[TBL] [Abstract][Full Text] [Related]
23. XS-2, a novel potent dual PI3K/mTOR inhibitor, exhibits high in vitro and in vivo anti-breast cancer activity and low toxicity with the potential to inhibit the invasion and migration of triple-negative breast cancer.
Xu S; Sun X; Luo L; Yang Y; Guo Q; Tang S; Jiang Z; Li Y; Han J; Gan W; Yang F; Zhang X; Liu Y; Sun C; He J; Liu M; Zuo D; Zhu W; Wu Y
Biomed Pharmacother; 2022 Nov; 155():113537. PubMed ID: 36113258
[TBL] [Abstract][Full Text] [Related]
24. Combination therapy with BYL719 and LEE011 is synergistic and causes a greater suppression of p-S6 in triple negative breast cancer.
Yuan Y; Wen W; Yost SE; Xing Q; Yan J; Han ES; Mortimer J; Yim JH
Sci Rep; 2019 May; 9(1):7509. PubMed ID: 31101835
[TBL] [Abstract][Full Text] [Related]
25. Radix Tetrastigma Extracts Enhance the Chemosensitivity in Triple-Negative Breast Cancer Via Inhibiting PI3K/Akt/mTOR-Mediated Autophagy.
Zhang S; Cui T; Duan Y; Zhang H; Wang B; Chen H; Ni J; Shen Y; Xiao-Ai Lv
Clin Breast Cancer; 2022 Feb; 22(2):89-97. PubMed ID: 34535390
[TBL] [Abstract][Full Text] [Related]
26. Selective activity of deguelin identifies therapeutic targets for androgen receptor-positive breast cancer.
Robles AJ; Cai S; Cichewicz RH; Mooberry SL
Breast Cancer Res Treat; 2016 Jun; 157(3):475-88. PubMed ID: 27255535
[TBL] [Abstract][Full Text] [Related]
27. [Molecular mechanisms of resistance to phosphatidyl inositol 3-kinase inhibitors in triple-negative breast cancer cells].
Zhang WL; Ma WJ; Chen S; Wu XZ; Zhang HR; Zhang JH
Zhonghua Zhong Liu Za Zhi; 2016 Aug; 38(8):578-88. PubMed ID: 27531477
[TBL] [Abstract][Full Text] [Related]
28. Involvement of AKT/PI3K Pathway in Sanguinarine's Induced Apoptosis and Cell Cycle Arrest in Triple-negative Breast Cancer Cells.
Messeha SS; Noel S; Zarmouh NO; Womble T; Latinwo LM; Soliman KFA
Cancer Genomics Proteomics; 2023; 20(4):323-342. PubMed ID: 37400144
[TBL] [Abstract][Full Text] [Related]
29. Indole-2-Carboxamide Derivative LG25 Inhibits Triple-Negative Breast Cancer Growth By Suppressing Akt/mTOR/NF-κB Signalling Pathway.
Xu X; Rajamanickam V; Shu S; Liu Z; Yan T; He J; Liu Z; Guo G; Liang G; Wang Y
Drug Des Devel Ther; 2019; 13():3539-3550. PubMed ID: 31631978
[TBL] [Abstract][Full Text] [Related]
30. Design, synthesis and biological evaluation of anilide (dicarboxylic acid) shikonin esters as antitumor agents through targeting PI3K/Akt/mTOR signaling pathway.
Ma Y; Yang X; Han H; Wen Z; Yang M; Zhang Y; Fu J; Wang X; Yin T; Lu G; Qi J; Lin H; Wang X; Yang Y
Bioorg Chem; 2021 Jun; 111():104872. PubMed ID: 33838560
[TBL] [Abstract][Full Text] [Related]
31. WBP2 Downregulation Inhibits Proliferation by Blocking YAP Transcription and the EGFR/PI3K/Akt Signaling Pathway in Triple Negative Breast Cancer.
Song H; Wu T; Xie D; Li D; Hua K; Hu J; Fang L
Cell Physiol Biochem; 2018; 48(5):1968-1982. PubMed ID: 30092563
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of autophagy by chloroquine prevents resistance to PI3K/AKT inhibitors and potentiates their antitumor effect in combination with paclitaxel in triple negative breast cancer models.
Cocco S; Leone A; Roca MS; Lombardi R; Piezzo M; Caputo R; Ciardiello C; Costantini S; Bruzzese F; Sisalli MJ; Budillon A; De Laurentiis M
J Transl Med; 2022 Jun; 20(1):290. PubMed ID: 35761360
[TBL] [Abstract][Full Text] [Related]
33. Pluronic-based micelle encapsulation potentiates myricetin-induced cytotoxicity in human glioblastoma cells.
Tang XJ; Huang KM; Gui H; Wang JJ; Lu JT; Dai LJ; Zhang L; Wang G
Int J Nanomedicine; 2016; 11():4991-5002. PubMed ID: 27757032
[TBL] [Abstract][Full Text] [Related]
34. Down-regulating GRP78 reverses pirarubicin resistance of triple negative breast cancer by miR-495-3p mimics and involves the p-AKT/mTOR pathway.
Liu M; Yang J; Lv W; Wang S; Du T; Zhang K; Wu Y; Feng X
Biosci Rep; 2022 Jan; 42(1):. PubMed ID: 34935899
[TBL] [Abstract][Full Text] [Related]
35. Total saponins of Bolbostemma paniculatum (maxim.) Franquet exert antitumor activity against MDA-MB-231 human breast cancer cells via inhibiting PI3K/Akt/mTOR pathway.
Dou JW; Shang RG; Lei XQ; Li KL; Guo ZZ; Ye K; Yang XJ; Li YW; Zhou YY; Yao J; Huang Q
BMC Complement Altern Med; 2019 Nov; 19(1):304. PubMed ID: 31703679
[TBL] [Abstract][Full Text] [Related]
36. Estrogen receptor beta increases sensitivity to enzalutamide in androgen receptor-positive triple-negative breast cancer.
Anestis A; Sarantis P; Theocharis S; Zoi I; Tryfonopoulos D; Korogiannos A; Koumarianou A; Xingi E; Thomaidou D; Kontos M; Papavassiliou AG; Karamouzis MV
J Cancer Res Clin Oncol; 2019 May; 145(5):1221-1233. PubMed ID: 30805773
[TBL] [Abstract][Full Text] [Related]
37. Triple negative breast cancer: shedding light onto the role of pi3k/akt/mtor pathway.
Massihnia D; Galvano A; Fanale D; Perez A; Castiglia M; Incorvaia L; Listì A; Rizzo S; Cicero G; Bazan V; Castorina S; Russo A
Oncotarget; 2016 Sep; 7(37):60712-60722. PubMed ID: 27474173
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of Akt/mTOR pathway overcomes intrinsic resistance to dasatinib in triple-negative breast cancer.
Haga Y; Higashisaka K; Yang L; Sekine N; Lin Y; Tsujino H; Nagano K; Tsutsumi Y
Biochem Biophys Res Commun; 2020 Dec; 533(4):672-678. PubMed ID: 33036754
[TBL] [Abstract][Full Text] [Related]
39. Pharmacological inhibition of the MEK5/ERK5 and PI3K/Akt signaling pathways synergistically reduces viability in triple-negative breast cancer.
Wright TD; Raybuck C; Bhatt A; Monlish D; Chakrabarty S; Wendekier K; Gartland N; Gupta M; Burow ME; Flaherty PT; Cavanaugh JE
J Cell Biochem; 2020 Feb; 121(2):1156-1168. PubMed ID: 31464004
[TBL] [Abstract][Full Text] [Related]
40. Luteolin suppresses androgen receptor-positive triple-negative breast cancer cell proliferation and metastasis by epigenetic regulation of MMP9 expression via the AKT/mTOR signaling pathway.
Wu HT; Lin J; Liu YE; Chen HF; Hsu KW; Lin SH; Peng KY; Lin KJ; Hsieh CC; Chen DR
Phytomedicine; 2021 Jan; 81():153437. PubMed ID: 33352494
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
